Heart shield for chemo: carvedilol may protect breast cancer Patients' hearts
NCT ID NCT04023110
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tested whether the heart medication carvedilol could safely protect breast cancer patients from heart damage caused by chemotherapy drugs like doxorubicin and trastuzumab. 68 women with early-stage breast cancer were assigned to either receive carvedilol or standard care based on their personal heart risk. The main goals were to see if the approach was safe, tolerable, and practical, not to prove it prevents heart failure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States